Gemphire Therapeutics Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 13th, 2016 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • June 13th, 2016 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • Michigan
THIS EMPLOYMENT AGREEMENT (this “Agreement”) by and between GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the “Company”) and [ ] (the “Executive”) is signed by the Company and the Executive on [ ], 201[_], and is made effective as of the IPO Date (the “Effective Date”).
POWERSCOURT OFFICE BUILDING LEASELease • June 13th, 2016 • Gemphire Therapeutics Inc. • Pharmaceutical preparations
THIS LEASE is made between the Landlord and Tenant hereinafter identified in Paragraph 1(b) and 1(c) hereof, respectively, and constitutes a Lease between the parties of the “demised premises” in the “Building” as defined in Paragraph 2 hereof on the terms and conditions and with and subject to the covenants and agreements of the parties hereinafter set forth.
LICENSE AGREEMENTLicense Agreement • June 13th, 2016 • Gemphire Therapeutics Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 16th day of April, 2011 (the “Effective Date”), by and between Michigan Life Therapeutics, LLC a corporation organized and existing under the laws of Michigan with offices at 2020 Shadford Road, Ann Arbor, MI 48104 (“LICENSEE”) and Pfizer Inc., a corporation organized and existing under the laws of Delaware with offices at 235 East 42nd Street, New York, NY 10017 (“PFIZER”). LICENSEE and PFIZER may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
GEMPHIRE THERAPEUTICS INC. FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTESNote Purchase Agreement • June 13th, 2016 • Gemphire Therapeutics Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT TO NOTE PURCHASE AGREEMENT AND CONVERTIBLE PROMISSORY NOTES (this “Fourth Amendment”) is made effective as of this 26th day of April 2016 (the “Fourth Amendment Date”), by and among GEMPHIRE THERAPEUTICS INC., a Delaware corporation (the “Company”), and the purchasers of the Company’s Convertible Promissory Notes identified on the signature page attached hereto (the “Purchasers”).
